Skip to main content
KyungdongPharm logo

KyungdongPharm — Investor Relations & Filings

Ticker · 011040 ISIN · KR7011040003 KO Manufacturing
Open in API
Filings indexed 303 across all filing types
Latest filing 2020-10-22 Major Shareholding Noti…
Country KR South Korea
Listing KO 011040

About KyungdongPharm

https://kdpharma.co.kr

KyungdongPharm is a pharmaceutical company engaged in the development, manufacturing, and distribution of medicines. Since its establishment in 1975, the company has focused on producing a broad portfolio of specialized therapeutic drugs and general pharmaceuticals. Its product lines encompass prescription medicines, with a focus on areas such as liver therapy, and over-the-counter products, including its prominent painkiller brand, 'Geunal-N'. The company also manufactures and supplies active pharmaceutical ingredients (APIs) and intermediates. Utilizing advanced production facilities and proprietary technology, KyungdongPharm is dedicated to developing high-quality medicines supported by clinical research to contribute to public health.

Recent filings

Filing Released Lang Actions
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a 'Correction Report' (정정신고) for a 'Stock Collateral Agreement' (주식 담보제공 계약) involving a major shareholder. This type of disclosure, which details changes in collateralized shares and financial obligations of major shareholders, falls under the category of general regulatory announcements and disclosures that do not fit into specific categories like earnings or dividends. Therefore, it is classified as a Regulatory Filing (RNS).
2020-10-22 Korean
기타경영사항(특허권취득)(자율공시)
Regulatory Filings Classification · 95% confidence The document is a short, voluntary disclosure (자율공시) regarding the acquisition of a patent by Kyungdong Pharmaceutical. It does not fit into financial reporting categories like 10-K or IR, nor is it a report announcement. As it is a specific regulatory disclosure regarding company operations/intellectual property that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2020-10-21 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Kyungdong Pharmaceutical regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which directly impacts the company's capital structure. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2020-10-20 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from Kyungdong Pharmaceutical regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which directly impacts the company's capital structure. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2020-10-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. This type of filing is a mandatory disclosure by company insiders (directors, executives, or major shareholders) regarding changes in their personal shareholdings or equity-linked securities. In the provided taxonomy, this corresponds to 'Director's Dealing' (DIRS), which covers insider transactions and changes in ownership status by company insiders.
2020-10-05 Korean
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Kyungdong Pharmaceutical regarding the 'Exercise of Conversion Rights' (전환청구권행사) for convertible bonds. This involves the conversion of debt into equity, which results in the issuance of new shares. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'Share Issue/Capital Change' (SHA) category.
2020-09-29 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.